28 research outputs found
Structure-Based Design of Novel G‑Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates
The
existing available antipsychotics have failed to manage the
cognitive impairment of schizophrenia and induced a number of seriously
undesirable effects. Trace amine-associated receptor 1 (TAAR1) has
emerged as an ideal target for the design of antischizophrenia drugs,
with the ability to mediate multiple psychological functions by sensing
endogenous amine-containing metabolites without the side effects of
catalepsy. In this work, a series of novel TAAR1 agonists were designed
based on the structural analysis of the TAAR1 activation pocket. Among
them, 6e displayed a potent TAAR1-Gs/Gq dual-pathway activation property, being different from that
of the clinical drug candidate SEP-363856 with only TAAR1-Gs pathway activation. In rodent models, 6e significantly
alleviated MK-801-induced schizophrenia-like cognitive phenotypes
without inducing catalepsy. Furthermore, 6e·HCl exhibited
favorable pharmacokinetic (T1/2 = 2.31
h, F = 39%) and safety properties. All these demonstrated
that 6e·HCl may be used as a novel drug candidate
for schizophrenia treatment
Structure-Based Design of Novel G‑Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates
The
existing available antipsychotics have failed to manage the
cognitive impairment of schizophrenia and induced a number of seriously
undesirable effects. Trace amine-associated receptor 1 (TAAR1) has
emerged as an ideal target for the design of antischizophrenia drugs,
with the ability to mediate multiple psychological functions by sensing
endogenous amine-containing metabolites without the side effects of
catalepsy. In this work, a series of novel TAAR1 agonists were designed
based on the structural analysis of the TAAR1 activation pocket. Among
them, 6e displayed a potent TAAR1-Gs/Gq dual-pathway activation property, being different from that
of the clinical drug candidate SEP-363856 with only TAAR1-Gs pathway activation. In rodent models, 6e significantly
alleviated MK-801-induced schizophrenia-like cognitive phenotypes
without inducing catalepsy. Furthermore, 6e·HCl exhibited
favorable pharmacokinetic (T1/2 = 2.31
h, F = 39%) and safety properties. All these demonstrated
that 6e·HCl may be used as a novel drug candidate
for schizophrenia treatment
Structure-Based Design of Novel G‑Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates
The
existing available antipsychotics have failed to manage the
cognitive impairment of schizophrenia and induced a number of seriously
undesirable effects. Trace amine-associated receptor 1 (TAAR1) has
emerged as an ideal target for the design of antischizophrenia drugs,
with the ability to mediate multiple psychological functions by sensing
endogenous amine-containing metabolites without the side effects of
catalepsy. In this work, a series of novel TAAR1 agonists were designed
based on the structural analysis of the TAAR1 activation pocket. Among
them, 6e displayed a potent TAAR1-Gs/Gq dual-pathway activation property, being different from that
of the clinical drug candidate SEP-363856 with only TAAR1-Gs pathway activation. In rodent models, 6e significantly
alleviated MK-801-induced schizophrenia-like cognitive phenotypes
without inducing catalepsy. Furthermore, 6e·HCl exhibited
favorable pharmacokinetic (T1/2 = 2.31
h, F = 39%) and safety properties. All these demonstrated
that 6e·HCl may be used as a novel drug candidate
for schizophrenia treatment
Structure-Based Design of Novel G‑Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates
The
existing available antipsychotics have failed to manage the
cognitive impairment of schizophrenia and induced a number of seriously
undesirable effects. Trace amine-associated receptor 1 (TAAR1) has
emerged as an ideal target for the design of antischizophrenia drugs,
with the ability to mediate multiple psychological functions by sensing
endogenous amine-containing metabolites without the side effects of
catalepsy. In this work, a series of novel TAAR1 agonists were designed
based on the structural analysis of the TAAR1 activation pocket. Among
them, 6e displayed a potent TAAR1-Gs/Gq dual-pathway activation property, being different from that
of the clinical drug candidate SEP-363856 with only TAAR1-Gs pathway activation. In rodent models, 6e significantly
alleviated MK-801-induced schizophrenia-like cognitive phenotypes
without inducing catalepsy. Furthermore, 6e·HCl exhibited
favorable pharmacokinetic (T1/2 = 2.31
h, F = 39%) and safety properties. All these demonstrated
that 6e·HCl may be used as a novel drug candidate
for schizophrenia treatment
Structure-Based Design of Novel G‑Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates
The
existing available antipsychotics have failed to manage the
cognitive impairment of schizophrenia and induced a number of seriously
undesirable effects. Trace amine-associated receptor 1 (TAAR1) has
emerged as an ideal target for the design of antischizophrenia drugs,
with the ability to mediate multiple psychological functions by sensing
endogenous amine-containing metabolites without the side effects of
catalepsy. In this work, a series of novel TAAR1 agonists were designed
based on the structural analysis of the TAAR1 activation pocket. Among
them, 6e displayed a potent TAAR1-Gs/Gq dual-pathway activation property, being different from that
of the clinical drug candidate SEP-363856 with only TAAR1-Gs pathway activation. In rodent models, 6e significantly
alleviated MK-801-induced schizophrenia-like cognitive phenotypes
without inducing catalepsy. Furthermore, 6e·HCl exhibited
favorable pharmacokinetic (T1/2 = 2.31
h, F = 39%) and safety properties. All these demonstrated
that 6e·HCl may be used as a novel drug candidate
for schizophrenia treatment
Structure-Based Design of Novel G‑Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates
The
existing available antipsychotics have failed to manage the
cognitive impairment of schizophrenia and induced a number of seriously
undesirable effects. Trace amine-associated receptor 1 (TAAR1) has
emerged as an ideal target for the design of antischizophrenia drugs,
with the ability to mediate multiple psychological functions by sensing
endogenous amine-containing metabolites without the side effects of
catalepsy. In this work, a series of novel TAAR1 agonists were designed
based on the structural analysis of the TAAR1 activation pocket. Among
them, 6e displayed a potent TAAR1-Gs/Gq dual-pathway activation property, being different from that
of the clinical drug candidate SEP-363856 with only TAAR1-Gs pathway activation. In rodent models, 6e significantly
alleviated MK-801-induced schizophrenia-like cognitive phenotypes
without inducing catalepsy. Furthermore, 6e·HCl exhibited
favorable pharmacokinetic (T1/2 = 2.31
h, F = 39%) and safety properties. All these demonstrated
that 6e·HCl may be used as a novel drug candidate
for schizophrenia treatment
Discovery of Novel Aryl Triazolone Dihydropyridines (ATDPs) Targeting Highly Conserved Residue W229 as Promising HIV‑1 NNRTIs
NNRTI is an important component of the highly active
antiretroviral
therapy (HAART), but the rapid emergence of drug resistance and poor
pharmacokinetics limited their clinical application. Herein, a series
of novel aryl triazolone dihydropyridines (ATDPs) were designed by
structure-guided design with the aim of improving drug resistance
profiles and pharmacokinetic profiles. Compound 10n (EC50 = 0.009–17.7 μM) exhibited the most active
potency, being superior to or comparable to that of doravirine (DOR)
against the whole tested viral panel. Molecular docking was performed
to clarify the reason for its higher resistance profiles. Moreover, 10n demonstrated excellent pharmacokinetic profile (T1/2 = 5.09 h, F = 108.96%)
compared that of DOR (T1/2 = 4.4 h, F = 57%). Additionally, 10n was also verified
to have no in vivo acute or subacute toxicity (LD50 > 2000 mg/kg), suggesting that 10n is worth
further investigation as a novel oral NNRTIs for HIV-1 therapy
Discovery of Novel Aryl Triazolone Dihydropyridines (ATDPs) Targeting Highly Conserved Residue W229 as Promising HIV‑1 NNRTIs
NNRTI is an important component of the highly active
antiretroviral
therapy (HAART), but the rapid emergence of drug resistance and poor
pharmacokinetics limited their clinical application. Herein, a series
of novel aryl triazolone dihydropyridines (ATDPs) were designed by
structure-guided design with the aim of improving drug resistance
profiles and pharmacokinetic profiles. Compound 10n (EC50 = 0.009–17.7 μM) exhibited the most active
potency, being superior to or comparable to that of doravirine (DOR)
against the whole tested viral panel. Molecular docking was performed
to clarify the reason for its higher resistance profiles. Moreover, 10n demonstrated excellent pharmacokinetic profile (T1/2 = 5.09 h, F = 108.96%)
compared that of DOR (T1/2 = 4.4 h, F = 57%). Additionally, 10n was also verified
to have no in vivo acute or subacute toxicity (LD50 > 2000 mg/kg), suggesting that 10n is worth
further investigation as a novel oral NNRTIs for HIV-1 therapy
Discovery of Novel Aryl Triazolone Dihydropyridines (ATDPs) Targeting Highly Conserved Residue W229 as Promising HIV‑1 NNRTIs
NNRTI is an important component of the highly active
antiretroviral
therapy (HAART), but the rapid emergence of drug resistance and poor
pharmacokinetics limited their clinical application. Herein, a series
of novel aryl triazolone dihydropyridines (ATDPs) were designed by
structure-guided design with the aim of improving drug resistance
profiles and pharmacokinetic profiles. Compound 10n (EC50 = 0.009–17.7 μM) exhibited the most active
potency, being superior to or comparable to that of doravirine (DOR)
against the whole tested viral panel. Molecular docking was performed
to clarify the reason for its higher resistance profiles. Moreover, 10n demonstrated excellent pharmacokinetic profile (T1/2 = 5.09 h, F = 108.96%)
compared that of DOR (T1/2 = 4.4 h, F = 57%). Additionally, 10n was also verified
to have no in vivo acute or subacute toxicity (LD50 > 2000 mg/kg), suggesting that 10n is worth
further investigation as a novel oral NNRTIs for HIV-1 therapy
Discovery of Novel Aryl Triazolone Dihydropyridines (ATDPs) Targeting Highly Conserved Residue W229 as Promising HIV‑1 NNRTIs
NNRTI is an important component of the highly active
antiretroviral
therapy (HAART), but the rapid emergence of drug resistance and poor
pharmacokinetics limited their clinical application. Herein, a series
of novel aryl triazolone dihydropyridines (ATDPs) were designed by
structure-guided design with the aim of improving drug resistance
profiles and pharmacokinetic profiles. Compound 10n (EC50 = 0.009–17.7 μM) exhibited the most active
potency, being superior to or comparable to that of doravirine (DOR)
against the whole tested viral panel. Molecular docking was performed
to clarify the reason for its higher resistance profiles. Moreover, 10n demonstrated excellent pharmacokinetic profile (T1/2 = 5.09 h, F = 108.96%)
compared that of DOR (T1/2 = 4.4 h, F = 57%). Additionally, 10n was also verified
to have no in vivo acute or subacute toxicity (LD50 > 2000 mg/kg), suggesting that 10n is worth
further investigation as a novel oral NNRTIs for HIV-1 therapy